RNAC - Cartesian Therapeutics Inc. logo

Cartesian Therapeutics Inc.

RNAC
โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$12today

Score Overview

1 Year
Score
Net Growth-18.14%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-47.19%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.5
Net Growth-499.29%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-98.26%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-325.13%
Net Trend40%
Net Income Consistency
Rev Growth-81.73%
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-325.13%
Net Trend40%
Net Income Consistency
Rev Growth-81.73%
Rev Trend60%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Cartesian Therapeutics Inc. has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. RNAC does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 6.18โ€”
1 Year2025-10-23
$ 9.00-31.33%
5 Years2021-10-22
$ 118.50-94.78%
10 Years2016-10-21
$ 500.70-98.77%
All Time2016-06-22
$ 420.00-98.53%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 1M-$ 153M$ 147M
2025$ 2M-$ 130M$ 125M
2024$ 38M-$ 77M$ 212M
2023$ 26M-$ 219M$ 76M
2022$ 110M$ 35M$ 134M
2021$ 85M-$ 25M$ 128M
2020$ 16M-$ 68M$ 138M
2019$ 6M-$ 55M$ 90M
2018$ 903K-$ 65M$ 37M
2017$ 207K-$ 65M$ 96M
IPO2016$ 8M-$ 36M$ 84M
RNAC - Cartesian Therapeutics Inc. logo

Cartesian Therapeutics Inc. fundamental performance

Between 2020 and 2025, revenue declined from $ 16M to $ 2M and net income went from -$ 68M to -$ 130M. Revenue increased in 2 of those 5 years; net income in 2.

Across Cartesian Therapeutics Inc.'s full reported history, from 2016 to 2025, revenue declined from $ 8M to $ 2M and net income went from -$ 36M to -$ 130M. Revenue increased in 60% of the years measured; net income in 40%.

Cartesian Therapeutics Inc. currently holds a 5-year HDB Score of 2.5 out of 10. How the HDB Score is calculated.

Membership

Explore RNAC with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies